The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
 
Andrzej J. Jakubowiak
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Skyline Diagnostics; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Skyline Diagnostics; Takeda
 
Agnes Benedict
Research Funding - Amgen (Inst)
 
Sumeet Panjabi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Ivan Houisse
Research Funding - Amgen (Inst)
 
Marco Campioni
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Andromachi Giannopoulou
Employment - Amgen
Travel, Accommodations, Expenses - Amgen
 
Sanjay Aggarwal
Employment - Amgen; Onyx
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Rafael Fonseca
Stock and Other Ownership Interests - Adaptive Biotechnologies
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Novartis; Onyx; Pharmacyclics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Novartis; Onyx; Pharmacyclics
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Fish testing
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Novartis; Onyx; Pharmacyclics